Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis
Nutrition, Metabolism & Cardiovascular Diseases | Oct 01, 2017
Gargiulo P, et al. - Glucagon-like peptide-1 (GLP-1) agonists' impacts on mortality, major nonfatal cardiovascular (CV) events, renal and retinal events in type 2 diabetics were investigated via a metanalysis. Evidence reported a significantly reduced all cause and CV mortality in diabetes mellitus (DM) patients in association with treatment with GLP-1 agonists.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
